Predicting carbapenem-resistant Pseudomonas aeruginosa infection risk using XGBoost model and explainability.

Journal: Scientific reports
Published Date:

Abstract

The prevalence and spread of carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global public health problem. This study aims to identify the risk factors of CRPA infection and construct a machine learning model to provide a prediction tool for clinical prevention and control. A total of 1949 patients with P.aeruginosa health care-associated infections (HAIs) were enrolled in this study. A total of 89 patients with CRPA infection and 89 patients with CSPA infection were matched 1:1. LASSO regression was used to screen the variables, and the XGBoost model was established (136 cases in the training set and 60 cases in the test set). Shapley additive explain (SHAP) method was used to explain the importance of variables. The area under the ROC curve (AUC) and calibration curve were used to evaluate the performance of the model. There were 89 cases of CRPA infection, and the CRPA infection rate was 4.57%. Respiratory tract was the most common source of infection, and ICU and hematology department were the high-risk departments. The AUC value of the XGBoost machine learning model in the training set was 0.987 (95%CI: 0.974-1.000), and the AUC value in the test set was 0.862 (95%CI: 0.750-0.974). The clinical decision curve also showed good results of the model. SHAP results showed that ICU admission, duration of central venous catheterization, use of carbapenems and fluoroquinolones were important factors for predicting CRPA infection. The XGBoost machine learning model is helpful for the early prevention and screening of CRPA infection in medical institutions. Infection control and clinical departments should carry out effective prevention and control for high-risk factors to reduce the occurrence of CRPA infection.

Authors

  • Yan Jiang
    Department of Nursing/Evidence-based Nursing Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Hong-Wei Wang
    Shanxi Medical University, Taiyuan, 030000, China.
  • Fang-Ying Tian
    Department of Hospital Infection, The Second Hospital of Shanxi Medical University, Taiyuan, 030000, China.
  • Yue Guo
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland.
  • Xiu-Mei Wang
    Department of Nursing, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, China. shiwang_0405@qq.com.